The effects of glyburide, a purportedly selective ATP-sensitive K+ channel antagonist, were studied on dihydropyridine (DHP)-sensitive (L-type) Ca2+ channel currents in rat aortic muscle cells. Whole-cell voltage-clamp Ba2+ currents (IBa) were recorded at a series of test potentials (Vτ) from -30 to +60 mV during 300-ms voltage steps from a holding potential of –80 mV. Bay k8644 (1 µM) increased peak divalent cation currents from 47.2 ± 15.1 to 102.6 ± 13.4 pA, and the current-voltage relationship curve was shifted 10 mV to the left (n = 5). The combination of 10 µM glyburide with 1 µM Bay k8644 further increased Bay k8644-enhanced IBa in each cell (average of 223.7 ± 26.4 pA, n = 5), and caused a further 10 mV hyperpolarizing (leftward) shift of the activation curve. The kinetics of IBa were also changed (more rapid inactivation) by glyburide. These stimulatory actions of glyburide were reversed on washout. In contrast to this apparent synergism with Bay k8644, 10 µM glyburide alone inhibited (rather than potentiated) IBa by about 20% at Vτ of 0, + 10, and +30 mV. Increasing glyburide concentration to 30 µM further inhibited the IBa to about 40-50% of controls. With the pure agonist isomer, 0.5 µM Bay R5417, at theoretically the same concentration of the minus enantiomer as is present in Bay k8644, IBa increased from 137 ± 18.3 pA to 354.2 ± 12.4 pA (n = 4). However, the combination of 10 µM glyburide and 0.5 µM Bay R5417 failed to further enhance IBa (tendency to block) at any VT, implying that the glyburide-Bay k8644 interaction may depend on both the stronger agonist and weaker antagonist isomers. IBa enhanced by 10 µM glyburide seem to flow through L-type Ca2+ channels because they were significantly blocked by the DHP antagonists, nimodipine and nisoldipine. Nimodipine (3 µM)inhibited the peak IBa by 30%, and 3 µM nisoldipine blocked IBa by almost 70%. Because glyburide produced opposite effects (block) when combined with the pure agonist enantiomer of Bay k8644, similar to the glyburide alone, but opposite to enhancement of racemic Bay k8644 agonist action, it is likely that there are multiple sites for modulation of vascular muscle L-type Ca2+ channels. Possible explanations include the existence of subtypes of DHP receptors, and glyburide actions that depend on the balance of DHP agonist versus antagonist influence. Glyburide could either be weakening the Ca2+ antagonist actions or acting at a separate sulfonylurea site that interacts with DHP sites.

Keywords:
Vasodilation, Aorta, Ca2+ influx, Ba2+ currents, ATP sensitivity, K+ channels, Ca2+ agonist, Ca2+ antagonist
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.